[go: up one dir, main page]

FR24C1027I1 - Agents antifongiques et leurs utilisations - Google Patents

Agents antifongiques et leurs utilisations

Info

Publication number
FR24C1027I1
FR24C1027I1 FR24C1027C FR24C1027C FR24C1027I1 FR 24C1027 I1 FR24C1027 I1 FR 24C1027I1 FR 24C1027 C FR24C1027 C FR 24C1027C FR 24C1027 C FR24C1027 C FR 24C1027C FR 24C1027 I1 FR24C1027 I1 FR 24C1027I1
Authority
FR
France
Prior art keywords
antifungal agents
antifungal
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1027C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NAPP PHARMACEUTICAL GROUP Ltd
Original Assignee
NAPP PHARMACEUTICAL GROUP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAPP PHARMACEUTICAL GROUP Ltd filed Critical NAPP PHARMACEUTICAL GROUP Ltd
Publication of FR24C1027I1 publication Critical patent/FR24C1027I1/fr
Application granted granted Critical
Publication of FR24C1027I2 publication Critical patent/FR24C1027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR24C1027C 2011-03-03 2024-06-20 Agents antifongiques et leurs utilisations Active FR24C1027I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448807P 2011-03-03 2011-03-03
PCT/US2012/027451 WO2012119065A2 (fr) 2011-03-03 2012-03-02 Agents antifongiques et leurs utilisations

Publications (2)

Publication Number Publication Date
FR24C1027I1 true FR24C1027I1 (fr) 2024-08-30
FR24C1027I2 FR24C1027I2 (fr) 2025-05-23

Family

ID=46758514

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1027C Active FR24C1027I2 (fr) 2011-03-03 2024-06-20 Agents antifongiques et leurs utilisations

Country Status (21)

Country Link
US (6) US8722619B2 (fr)
EP (2) EP3192803B1 (fr)
JP (4) JP5809296B2 (fr)
CN (2) CN106279369B (fr)
CA (2) CA2865791C (fr)
CY (2) CY1119709T1 (fr)
DK (1) DK2680873T3 (fr)
ES (1) ES2645074T3 (fr)
FI (1) FIC20240022I1 (fr)
FR (1) FR24C1027I2 (fr)
HR (1) HRP20171579T8 (fr)
HU (2) HUE036778T2 (fr)
LT (2) LT2680873T (fr)
NL (1) NL301280I2 (fr)
NO (1) NO2680873T3 (fr)
PL (1) PL2680873T3 (fr)
PT (1) PT2680873T (fr)
RS (1) RS56426B1 (fr)
SI (1) SI2680873T1 (fr)
SM (1) SMT201700460T1 (fr)
WO (1) WO2012119065A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119065A2 (fr) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Agents antifongiques et leurs utilisations
DK3677252T3 (da) * 2012-03-19 2023-10-02 Cidara Therapeutics Inc Doseringsregimer for echinocandin-klasse forbindelser
WO2015035102A2 (fr) * 2013-09-04 2015-03-12 Cidara Therapeutics, Inc. Compositions et méthodes pour le traitement d'infections fongiques
US20170042162A1 (en) * 2014-04-28 2017-02-16 University Of Central Florida Research Foundation, Inc. Compositions, methods of making a composition, and methods of use
WO2016201283A1 (fr) * 2015-06-12 2016-12-15 Cidara Therapeutics, Inc. Agents antifongiques
WO2017049102A1 (fr) * 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Méthodes de traitement d'infections fongiques
CN106674333B (zh) * 2015-11-06 2020-10-27 博瑞生物医药（苏州）股份有限公司 一种环肽类抗真菌化合物及其制备方法
US10369188B2 (en) 2016-01-08 2019-08-06 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
JP7224916B2 (ja) * 2016-03-16 2023-02-20 シダラ セラピューティクス インコーポレーテッド 真菌感染の処置のための投薬レジメン
EP3512539A4 (fr) 2016-09-13 2020-07-29 Prothera Biologics, Inc. Procédés de traitement d'une maladie pulmonaire à l'aide de protéines inhibitrices d'inter-alpha
WO2018102407A1 (fr) * 2016-11-29 2018-06-07 Cidara Therapeutics, Inc Procédés de prévention d'infections fongiques
MA47437A (fr) * 2017-01-31 2019-12-11 Cidara Therapeutics Inc Procédés de traitement d'infections fongiques
US20200057077A1 (en) 2017-04-25 2020-02-20 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
US11197909B2 (en) 2017-07-12 2021-12-14 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
JP7373508B2 (ja) * 2018-06-15 2023-11-02 シダラ セラピューティクス インコーポレーテッド エキノカンジン抗真菌剤の合成
US12060439B2 (en) 2018-10-25 2024-08-13 Napp Pharmaceutical Group Limited Polymorph of echinocandin antifungal agent
CN114616238B (zh) 2019-12-06 2025-04-11 福建盛迪医药有限公司 棘白菌素类似物及其制备方法
CN117255797A (zh) 2021-06-03 2023-12-19 上海森辉医药有限公司 一种阿尼芬净衍生物的制备方法
CN115850383A (zh) * 2022-12-15 2023-03-28 江苏九阳生物制药有限公司 一种雷扎芬净纯化方法
CN116903706B (zh) * 2023-06-13 2024-05-17 深圳市祥根生物有限公司 一种棘白菌素类药物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) * 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
AU674233B2 (en) 1993-05-04 1996-12-12 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
WO1995008341A1 (fr) * 1993-09-22 1995-03-30 Merck & Co., Inc. Composes antifongiques et anti-pneumocystose, compositions les contenant et procedes d'utilisation
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) * 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
DE69615535T2 (de) 1995-01-26 2002-05-02 Merck & Co., Inc. Neue fungizide cyclohexapeptide
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
PE63998A1 (es) 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
IL143563A0 (en) * 1998-12-09 2002-04-21 Lilly Co Eli Purification of echinocandin cyclopeptide compounds
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000051564A1 (fr) 1999-03-03 2000-09-08 Eli Lilly And Company Formulations pharmaceutiques d'echinocandine contenant des tensioactifs formant des micelles
CN1345230A (zh) 1999-03-03 2002-04-17 伊莱利利公司 口服ecb药物制剂和药物组合物的制备方法
US6309622B1 (en) 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
CN1355699A (zh) 1999-04-16 2002-06-26 藤泽药品工业株式会社 抗真菌组合物
US6610822B2 (en) 2000-09-01 2003-08-26 Merck & Co., Inc. Purification process
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
WO2005014777A2 (fr) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Procedes et compositions pour augmenter l'efficacite de substances actives d'un point de vue biologique
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
EP1654036B1 (fr) 2003-07-22 2007-12-26 Theravance, Inc. Utilisation d'un agent antifongique a base d'echinocandines conjointement avec un agent antibacterien glycopeptidique
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
AU2006272568B2 (en) 2005-07-26 2012-06-28 Merck Sharp & Dohme Corp. Assays for resistance to echinocandin-class drugs
WO2007113386A1 (fr) * 2006-03-31 2007-10-11 Karyon-Ctt Ltd Conjugués peptidiques
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
CA2753497C (fr) 2009-02-25 2016-07-05 Stiefel Research Australia Pty Ltd Composition de mousse a usage topique
SI2427477T1 (sl) * 2009-05-07 2014-06-30 Dsm Sinochem Pharmaceuticals Netherlands B.V. Postopek priprave ciklopeptidov
AU2010286704B2 (en) 2009-08-26 2016-10-20 Ptc Therapeutics, Inc. Methods for the prevention and treatment of cerebral ischemia
EP2470190A4 (fr) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc Dérivés d échinocandine
WO2011089214A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de carbamates liés à des supports
WO2012119065A2 (fr) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Agents antifongiques et leurs utilisations
EP2739652B1 (fr) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Inhibiteurs cahgt1p à utiliser dans le traitement de la candidose
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
DK3677252T3 (da) 2012-03-19 2023-10-02 Cidara Therapeutics Inc Doseringsregimer for echinocandin-klasse forbindelser
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (fr) 2013-01-18 2014-07-24 University Of Utah Research Foundation Pompe osmotique à libération modifiée pour administration intravaginale de médicament réagissant au ph
WO2014124504A1 (fr) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions et méthodes de traitement de biofilms
EP2968381A4 (fr) 2013-03-15 2016-11-30 Sidney Hecht Conjugués de médicament-séquence de liaison du sucre
US9539223B2 (en) 2013-05-01 2017-01-10 Neoculi Pty Ltd Methods for treating bacterial infections
WO2015035102A2 (fr) 2013-09-04 2015-03-12 Cidara Therapeutics, Inc. Compositions et méthodes pour le traitement d'infections fongiques
WO2017049105A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations pour le traitement d'infections fongiques
WO2017049102A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Méthodes de traitement d'infections fongiques
US10369188B2 (en) 2016-01-08 2019-08-06 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
JP7224916B2 (ja) 2016-03-16 2023-02-20 シダラ セラピューティクス インコーポレーテッド 真菌感染の処置のための投薬レジメン
US20190307843A1 (en) 2016-11-01 2019-10-10 Cidara Therapeutics, Inc. Single dose methods for preventing and treating fungal infections
WO2018102407A1 (fr) 2016-11-29 2018-06-07 Cidara Therapeutics, Inc Procédés de prévention d'infections fongiques
MA47437A (fr) 2017-01-31 2019-12-11 Cidara Therapeutics Inc Procédés de traitement d'infections fongiques
WO2018187574A1 (fr) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions et procédés de traitement d'infections fongiques
WO2018191692A1 (fr) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
US11197909B2 (en) 2017-07-12 2021-12-14 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
AU2018311375A1 (en) 2017-08-03 2020-03-12 Napp Pharmaceutical Group Limited Methods for preventing and treating intra-abdominal candidiasis
JP7373508B2 (ja) 2018-06-15 2023-11-02 シダラ セラピューティクス インコーポレーテッド エキノカンジン抗真菌剤の合成

Also Published As

Publication number Publication date
SI2680873T1 (sl) 2017-12-29
JP6111447B2 (ja) 2017-04-12
CN103889221B (zh) 2016-08-31
JP2014516339A (ja) 2014-07-10
CY1119709T1 (el) 2018-06-27
US20250289852A1 (en) 2025-09-18
CN106279369A (zh) 2017-01-04
FR24C1027I2 (fr) 2025-05-23
ES2645074T3 (es) 2017-12-04
RS56426B1 (sr) 2018-01-31
US20150024997A1 (en) 2015-01-22
HRP20171579T8 (hr) 2018-12-14
DK2680873T3 (en) 2017-10-30
CN103889221A (zh) 2014-06-25
FIC20240022I1 (fi) 2024-06-19
HRP20171579T1 (hr) 2018-02-09
NL301280I2 (nl) 2024-08-01
HUE036778T2 (hu) 2018-07-30
LT2680873T (lt) 2017-11-27
US20170253635A1 (en) 2017-09-07
EP2680873A4 (fr) 2015-08-26
CA2865791C (fr) 2019-10-08
US12344680B2 (en) 2025-07-01
WO2012119065A3 (fr) 2014-03-13
EP3192803A1 (fr) 2017-07-19
US20220162263A1 (en) 2022-05-26
CN106279369B (zh) 2020-02-11
CY2024022I2 (el) 2025-03-28
SMT201700460T1 (it) 2018-01-11
ES2645074T8 (es) 2018-09-28
JP2016029052A (ja) 2016-03-03
NO2680873T3 (fr) 2018-01-06
CA2865791A1 (fr) 2012-09-07
EP2680873B1 (fr) 2017-08-09
CA3053850A1 (fr) 2012-09-07
CY2024022I1 (el) 2025-03-28
JP2017132770A (ja) 2017-08-03
HUS2400021I1 (hu) 2024-07-28
WO2012119065A2 (fr) 2012-09-07
US9217014B2 (en) 2015-12-22
JP2018118977A (ja) 2018-08-02
US8722619B2 (en) 2014-05-13
EP2680873A2 (fr) 2014-01-08
PL2680873T3 (pl) 2018-01-31
US9676821B2 (en) 2017-06-13
JP5809296B2 (ja) 2015-11-10
JP6302108B2 (ja) 2018-03-28
US20130244930A1 (en) 2013-09-19
LTPA2024520I1 (fr) 2024-07-10
EP3192803B1 (fr) 2020-12-09
PT2680873T (pt) 2017-11-01
US20160075740A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
FR24C1027I2 (fr) Agents antifongiques et leurs utilisations
EP2794654A4 (fr) Anticorps anti-phf-tau et leurs utilisations
EP2885318A4 (fr) Conjugués peptides-dendrimères et leurs utilisations
ME03063B (fr) Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
EP2705039A4 (fr) Inhibiteurs de bromodomaines et leurs utilisations
EP2683406A4 (fr) Anticorps anti-cd40 et leurs utilisations
EP2721031A4 (fr) Inhibiteurs à bromodomaine et leurs utilisations
EP2668210A4 (fr) Anticorps anti-kit et leurs utilisations
EP2771020A4 (fr) Dérivés n-acyldipeptides et leurs utilisations
EP2906255A4 (fr) Composés anti-sens et leurs utilisations
EP2600878A4 (fr) Lymphocytes b régulateurs et leurs utilisations
EP2888238A4 (fr) Composés benzocyclo-octyne et leurs utilisations
EP2718325A4 (fr) Anticorps anti-psgl-1 et leurs utilisations
EP2935283A4 (fr) Inhibiteurs de la glycosidase et leurs utilisations
EP2726103A4 (fr) Anticorps anti-properdine et leurs utilisations
EP2744338A4 (fr) Inhibiteurs de glycosidase sélectifs et leurs utilisations
EP2714023A4 (fr) Nano-ensembles polymères réticulés et leurs utilisations
EP2608785A4 (fr) Lipomacrocycles et leurs utilisations
EP2875014A4 (fr) Médicaments anti-mucus et leurs utilisations
EP2616468A4 (fr) Hétéroaryles condensés et leurs utilisations
EP2718326A4 (fr) Anticorps contre g-csfr et leurs utilisations
EP2699272A4 (fr) Agents de contraste et utilisations associées
EP2627324A4 (fr) Benzamides substitués et leurs utilisations
EP2928875A4 (fr) Composé antifongique et ses utilisations
EP2768797A4 (fr) Nouvelles curcumines modifiées et leurs utilisations